ESMO Asia Congress 2023 | OncologyPRO
In Chinese patients with mHSPC, DARO combined with ADT + DOC improved overall survival, delayed progression to CRPC and PSA, with a safety profile similar to placebo. DARO showed significant benefits in PSA responses and treatment duration, consistent with the ARASENS study's overall findings.
Related Clinical Trials
Reference News
ESMO Asia Congress 2023 | OncologyPRO
In Chinese patients with mHSPC, DARO combined with ADT + DOC improved overall survival, delayed progression to CRPC and PSA, with a safety profile similar to placebo. DARO showed significant benefits in PSA responses and treatment duration, consistent with the ARASENS study's overall findings.